Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
Identifieur interne : 001256 ( Ncbi/Merge ); précédent : 001255; suivant : 001257Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
Auteurs : Caterina Fattorusso [Italie] ; Sandra Gemma ; Stefania Butini ; Paul Huleatt ; Bruno Catalanotti ; Marco Persico ; Meri De Angelis ; Isabella Fiorini ; Vito Nacci ; Anna Ramunno ; Manuela Rodriquez ; Giovanni Greco ; Ettore Novellino ; Alberto Bergamini ; Stefano Marini ; Massimo Coletta ; Giovanni Maga ; Silvio Spadari ; Giuseppe CampianiSource :
- Journal of medicinal chemistry [ 0022-2623 ] ; 2005.
Descripteurs français
- KwdFr :
- Agents antiVIH (), Agents antiVIH (pharmacologie), Agents antiVIH (synthèse chimique), Animaux, Cellules cultivées, Conception de médicament, Humains, Inhibiteurs de la transcriptase inverse (), Inhibiteurs de la transcriptase inverse (pharmacologie), Inhibiteurs de la transcriptase inverse (synthèse chimique), Macrophages (), Macrophages (virologie), Modèles moléculaires, Mutation, Oxazépines (), Oxazépines (pharmacologie), Oxazépines (synthèse chimique), Pyrroles (), Pyrroles (pharmacologie), Pyrroles (synthèse chimique), Relation structure-activité, Réplication virale (), Résistance virale aux médicaments, Sites de fixation, Souris, Stéréoisomérie, Synergie des médicaments, Séquence conservée, Séquence d'acides aminés, Transcriptase inverse du VIH (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique), Zidovudine (pharmacologie).
- MESH :
- génétique : VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- pharmacologie : Agents antiVIH, Inhibiteurs de la transcriptase inverse, Oxazépines, Pyrroles, Zidovudine.
- synthèse chimique : Agents antiVIH, Inhibiteurs de la transcriptase inverse, Oxazépines, Pyrroles.
- virologie : Macrophages.
- Agents antiVIH, Animaux, Cellules cultivées, Conception de médicament, Humains, Inhibiteurs de la transcriptase inverse, Macrophages, Modèles moléculaires, Mutation, Oxazépines, Pyrroles, Relation structure-activité, Réplication virale, Résistance virale aux médicaments, Sites de fixation, Souris, Stéréoisomérie, Synergie des médicaments, Séquence conservée, Séquence d'acides aminés, Transcriptase inverse du VIH, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
English descriptors
- KwdEn :
- Amino Acid Sequence, Animals, Anti-HIV Agents (chemical synthesis), Anti-HIV Agents (chemistry), Anti-HIV Agents (pharmacology), Binding Sites, Cells, Cultured, Conserved Sequence, Drug Design, Drug Resistance, Viral, Drug Synergism, HIV Reverse Transcriptase (chemistry), HIV-1 (drug effects), HIV-1 (genetics), Humans, Macrophages (drug effects), Macrophages (virology), Mice, Models, Molecular, Mutation, Oxazepines (chemical synthesis), Oxazepines (chemistry), Oxazepines (pharmacology), Pyrroles (chemical synthesis), Pyrroles (chemistry), Pyrroles (pharmacology), Reverse Transcriptase Inhibitors (chemical synthesis), Reverse Transcriptase Inhibitors (chemistry), Reverse Transcriptase Inhibitors (pharmacology), Stereoisomerism, Structure-Activity Relationship, Virus Replication (drug effects), Zidovudine (pharmacology).
- MESH :
- chemical , chemical synthesis : Anti-HIV Agents, Oxazepines, Pyrroles, Reverse Transcriptase Inhibitors.
- chemical , chemistry : Anti-HIV Agents, HIV Reverse Transcriptase, Oxazepines, Pyrroles, Reverse Transcriptase Inhibitors.
- chemical , pharmacology : Anti-HIV Agents, Oxazepines, Pyrroles, Reverse Transcriptase Inhibitors, Zidovudine.
- drug effects : HIV-1, Macrophages, Virus Replication.
- genetics : HIV-1.
- virology : Macrophages.
- Amino Acid Sequence, Animals, Binding Sites, Cells, Cultured, Conserved Sequence, Drug Design, Drug Resistance, Viral, Drug Synergism, Humans, Mice, Models, Molecular, Mutation, Stereoisomerism, Structure-Activity Relationship.
Abstract
Pyrrolobenzoxazepinones (PBOs) represent a new class of human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) whose prototype is 5. Molecular modeling studies based on the X-ray structures of HIV-1 RT prompted the synthesis of novel analogues which were tested as anti-HIV agents. The PBO derivatives specifically designed to target the highly conserved amino acid residues within the beta12-beta13 hairpin, namely primer grip, proved to be very potent against the most common mutant enzymes, including the highly resistant K103N mutant strain. Structure-activity relationships (SARs) are discussed in terms of a possible interaction with the RT binding site, depending on the nature of the substituents at C-6. Among the pyrrolobenzoxazepines investigated, 15c appeared to be the most promising NNRTI of the series characterized by potent antiviral activity, broad spectrum, and low cytotoxicity. 15c showed synergistic antiviral activity with AZT.
DOI: 10.1021/jm050257d
PubMed: 16279773
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002453
- to stream PubMed, to step Curation: 002453
- to stream PubMed, to step Checkpoint: 002472
Links to Exploration step
pubmed:16279773Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.</title><author><name sortKey="Fattorusso, Caterina" sort="Fattorusso, Caterina" uniqKey="Fattorusso C" first="Caterina" last="Fattorusso">Caterina Fattorusso</name><affiliation wicri:level="1"><nlm:affiliation>Dipartimento di Chimica delle Sostanze Naturali, Universita' di Napoli Federico II, via D. Montesano 49, 80131 Napoli, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Dipartimento di Chimica delle Sostanze Naturali, Universita' di Napoli Federico II, via D. Montesano 49, 80131 Napoli</wicri:regionArea><wicri:noRegion>80131 Napoli</wicri:noRegion></affiliation></author><author><name sortKey="Gemma, Sandra" sort="Gemma, Sandra" uniqKey="Gemma S" first="Sandra" last="Gemma">Sandra Gemma</name></author><author><name sortKey="Butini, Stefania" sort="Butini, Stefania" uniqKey="Butini S" first="Stefania" last="Butini">Stefania Butini</name></author><author><name sortKey="Huleatt, Paul" sort="Huleatt, Paul" uniqKey="Huleatt P" first="Paul" last="Huleatt">Paul Huleatt</name></author><author><name sortKey="Catalanotti, Bruno" sort="Catalanotti, Bruno" uniqKey="Catalanotti B" first="Bruno" last="Catalanotti">Bruno Catalanotti</name></author><author><name sortKey="Persico, Marco" sort="Persico, Marco" uniqKey="Persico M" first="Marco" last="Persico">Marco Persico</name></author><author><name sortKey="De Angelis, Meri" sort="De Angelis, Meri" uniqKey="De Angelis M" first="Meri" last="De Angelis">Meri De Angelis</name></author><author><name sortKey="Fiorini, Isabella" sort="Fiorini, Isabella" uniqKey="Fiorini I" first="Isabella" last="Fiorini">Isabella Fiorini</name></author><author><name sortKey="Nacci, Vito" sort="Nacci, Vito" uniqKey="Nacci V" first="Vito" last="Nacci">Vito Nacci</name></author><author><name sortKey="Ramunno, Anna" sort="Ramunno, Anna" uniqKey="Ramunno A" first="Anna" last="Ramunno">Anna Ramunno</name></author><author><name sortKey="Rodriquez, Manuela" sort="Rodriquez, Manuela" uniqKey="Rodriquez M" first="Manuela" last="Rodriquez">Manuela Rodriquez</name></author><author><name sortKey="Greco, Giovanni" sort="Greco, Giovanni" uniqKey="Greco G" first="Giovanni" last="Greco">Giovanni Greco</name></author><author><name sortKey="Novellino, Ettore" sort="Novellino, Ettore" uniqKey="Novellino E" first="Ettore" last="Novellino">Ettore Novellino</name></author><author><name sortKey="Bergamini, Alberto" sort="Bergamini, Alberto" uniqKey="Bergamini A" first="Alberto" last="Bergamini">Alberto Bergamini</name></author><author><name sortKey="Marini, Stefano" sort="Marini, Stefano" uniqKey="Marini S" first="Stefano" last="Marini">Stefano Marini</name></author><author><name sortKey="Coletta, Massimo" sort="Coletta, Massimo" uniqKey="Coletta M" first="Massimo" last="Coletta">Massimo Coletta</name></author><author><name sortKey="Maga, Giovanni" sort="Maga, Giovanni" uniqKey="Maga G" first="Giovanni" last="Maga">Giovanni Maga</name></author><author><name sortKey="Spadari, Silvio" sort="Spadari, Silvio" uniqKey="Spadari S" first="Silvio" last="Spadari">Silvio Spadari</name></author><author><name sortKey="Campiani, Giuseppe" sort="Campiani, Giuseppe" uniqKey="Campiani G" first="Giuseppe" last="Campiani">Giuseppe Campiani</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16279773</idno><idno type="pmid">16279773</idno><idno type="doi">10.1021/jm050257d</idno><idno type="wicri:Area/PubMed/Corpus">002453</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002453</idno><idno type="wicri:Area/PubMed/Curation">002453</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002453</idno><idno type="wicri:Area/PubMed/Checkpoint">002472</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002472</idno><idno type="wicri:Area/Ncbi/Merge">001256</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.</title><author><name sortKey="Fattorusso, Caterina" sort="Fattorusso, Caterina" uniqKey="Fattorusso C" first="Caterina" last="Fattorusso">Caterina Fattorusso</name><affiliation wicri:level="1"><nlm:affiliation>Dipartimento di Chimica delle Sostanze Naturali, Universita' di Napoli Federico II, via D. Montesano 49, 80131 Napoli, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Dipartimento di Chimica delle Sostanze Naturali, Universita' di Napoli Federico II, via D. Montesano 49, 80131 Napoli</wicri:regionArea><wicri:noRegion>80131 Napoli</wicri:noRegion></affiliation></author><author><name sortKey="Gemma, Sandra" sort="Gemma, Sandra" uniqKey="Gemma S" first="Sandra" last="Gemma">Sandra Gemma</name></author><author><name sortKey="Butini, Stefania" sort="Butini, Stefania" uniqKey="Butini S" first="Stefania" last="Butini">Stefania Butini</name></author><author><name sortKey="Huleatt, Paul" sort="Huleatt, Paul" uniqKey="Huleatt P" first="Paul" last="Huleatt">Paul Huleatt</name></author><author><name sortKey="Catalanotti, Bruno" sort="Catalanotti, Bruno" uniqKey="Catalanotti B" first="Bruno" last="Catalanotti">Bruno Catalanotti</name></author><author><name sortKey="Persico, Marco" sort="Persico, Marco" uniqKey="Persico M" first="Marco" last="Persico">Marco Persico</name></author><author><name sortKey="De Angelis, Meri" sort="De Angelis, Meri" uniqKey="De Angelis M" first="Meri" last="De Angelis">Meri De Angelis</name></author><author><name sortKey="Fiorini, Isabella" sort="Fiorini, Isabella" uniqKey="Fiorini I" first="Isabella" last="Fiorini">Isabella Fiorini</name></author><author><name sortKey="Nacci, Vito" sort="Nacci, Vito" uniqKey="Nacci V" first="Vito" last="Nacci">Vito Nacci</name></author><author><name sortKey="Ramunno, Anna" sort="Ramunno, Anna" uniqKey="Ramunno A" first="Anna" last="Ramunno">Anna Ramunno</name></author><author><name sortKey="Rodriquez, Manuela" sort="Rodriquez, Manuela" uniqKey="Rodriquez M" first="Manuela" last="Rodriquez">Manuela Rodriquez</name></author><author><name sortKey="Greco, Giovanni" sort="Greco, Giovanni" uniqKey="Greco G" first="Giovanni" last="Greco">Giovanni Greco</name></author><author><name sortKey="Novellino, Ettore" sort="Novellino, Ettore" uniqKey="Novellino E" first="Ettore" last="Novellino">Ettore Novellino</name></author><author><name sortKey="Bergamini, Alberto" sort="Bergamini, Alberto" uniqKey="Bergamini A" first="Alberto" last="Bergamini">Alberto Bergamini</name></author><author><name sortKey="Marini, Stefano" sort="Marini, Stefano" uniqKey="Marini S" first="Stefano" last="Marini">Stefano Marini</name></author><author><name sortKey="Coletta, Massimo" sort="Coletta, Massimo" uniqKey="Coletta M" first="Massimo" last="Coletta">Massimo Coletta</name></author><author><name sortKey="Maga, Giovanni" sort="Maga, Giovanni" uniqKey="Maga G" first="Giovanni" last="Maga">Giovanni Maga</name></author><author><name sortKey="Spadari, Silvio" sort="Spadari, Silvio" uniqKey="Spadari S" first="Silvio" last="Spadari">Silvio Spadari</name></author><author><name sortKey="Campiani, Giuseppe" sort="Campiani, Giuseppe" uniqKey="Campiani G" first="Giuseppe" last="Campiani">Giuseppe Campiani</name></author></analytic><series><title level="j">Journal of medicinal chemistry</title><idno type="ISSN">0022-2623</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Anti-HIV Agents (chemical synthesis)</term><term>Anti-HIV Agents (chemistry)</term><term>Anti-HIV Agents (pharmacology)</term><term>Binding Sites</term><term>Cells, Cultured</term><term>Conserved Sequence</term><term>Drug Design</term><term>Drug Resistance, Viral</term><term>Drug Synergism</term><term>HIV Reverse Transcriptase (chemistry)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (genetics)</term><term>Humans</term><term>Macrophages (drug effects)</term><term>Macrophages (virology)</term><term>Mice</term><term>Models, Molecular</term><term>Mutation</term><term>Oxazepines (chemical synthesis)</term><term>Oxazepines (chemistry)</term><term>Oxazepines (pharmacology)</term><term>Pyrroles (chemical synthesis)</term><term>Pyrroles (chemistry)</term><term>Pyrroles (pharmacology)</term><term>Reverse Transcriptase Inhibitors (chemical synthesis)</term><term>Reverse Transcriptase Inhibitors (chemistry)</term><term>Reverse Transcriptase Inhibitors (pharmacology)</term><term>Stereoisomerism</term><term>Structure-Activity Relationship</term><term>Virus Replication (drug effects)</term><term>Zidovudine (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agents antiVIH ()</term><term>Agents antiVIH (pharmacologie)</term><term>Agents antiVIH (synthèse chimique)</term><term>Animaux</term><term>Cellules cultivées</term><term>Conception de médicament</term><term>Humains</term><term>Inhibiteurs de la transcriptase inverse ()</term><term>Inhibiteurs de la transcriptase inverse (pharmacologie)</term><term>Inhibiteurs de la transcriptase inverse (synthèse chimique)</term><term>Macrophages ()</term><term>Macrophages (virologie)</term><term>Modèles moléculaires</term><term>Mutation</term><term>Oxazépines ()</term><term>Oxazépines (pharmacologie)</term><term>Oxazépines (synthèse chimique)</term><term>Pyrroles ()</term><term>Pyrroles (pharmacologie)</term><term>Pyrroles (synthèse chimique)</term><term>Relation structure-activité</term><term>Réplication virale ()</term><term>Résistance virale aux médicaments</term><term>Sites de fixation</term><term>Souris</term><term>Stéréoisomérie</term><term>Synergie des médicaments</term><term>Séquence conservée</term><term>Séquence d'acides aminés</term><term>Transcriptase inverse du VIH ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique)</term><term>Zidovudine (pharmacologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Anti-HIV Agents</term><term>Oxazepines</term><term>Pyrroles</term><term>Reverse Transcriptase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Anti-HIV Agents</term><term>HIV Reverse Transcriptase</term><term>Oxazepines</term><term>Pyrroles</term><term>Reverse Transcriptase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term><term>Oxazepines</term><term>Pyrroles</term><term>Reverse Transcriptase Inhibitors</term><term>Zidovudine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>Macrophages</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents antiVIH</term><term>Inhibiteurs de la transcriptase inverse</term><term>Oxazépines</term><term>Pyrroles</term><term>Zidovudine</term></keywords><keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Agents antiVIH</term><term>Inhibiteurs de la transcriptase inverse</term><term>Oxazépines</term><term>Pyrroles</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Macrophages</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Macrophages</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Binding Sites</term><term>Cells, Cultured</term><term>Conserved Sequence</term><term>Drug Design</term><term>Drug Resistance, Viral</term><term>Drug Synergism</term><term>Humans</term><term>Mice</term><term>Models, Molecular</term><term>Mutation</term><term>Stereoisomerism</term><term>Structure-Activity Relationship</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Agents antiVIH</term><term>Animaux</term><term>Cellules cultivées</term><term>Conception de médicament</term><term>Humains</term><term>Inhibiteurs de la transcriptase inverse</term><term>Macrophages</term><term>Modèles moléculaires</term><term>Mutation</term><term>Oxazépines</term><term>Pyrroles</term><term>Relation structure-activité</term><term>Réplication virale</term><term>Résistance virale aux médicaments</term><term>Sites de fixation</term><term>Souris</term><term>Stéréoisomérie</term><term>Synergie des médicaments</term><term>Séquence conservée</term><term>Séquence d'acides aminés</term><term>Transcriptase inverse du VIH</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pyrrolobenzoxazepinones (PBOs) represent a new class of human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) whose prototype is 5. Molecular modeling studies based on the X-ray structures of HIV-1 RT prompted the synthesis of novel analogues which were tested as anti-HIV agents. The PBO derivatives specifically designed to target the highly conserved amino acid residues within the beta12-beta13 hairpin, namely primer grip, proved to be very potent against the most common mutant enzymes, including the highly resistant K103N mutant strain. Structure-activity relationships (SARs) are discussed in terms of a possible interaction with the RT binding site, depending on the nature of the substituents at C-6. Among the pyrrolobenzoxazepines investigated, 15c appeared to be the most promising NNRTI of the series characterized by potent antiviral activity, broad spectrum, and low cytotoxicity. 15c showed synergistic antiviral activity with AZT.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16279773</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-2623</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>23</Issue><PubDate><Year>2005</Year><Month>Nov</Month><Day>17</Day></PubDate></JournalIssue><Title>Journal of medicinal chemistry</Title><ISOAbbreviation>J. Med. Chem.</ISOAbbreviation></Journal><ArticleTitle>Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.</ArticleTitle><Pagination><MedlinePgn>7153-65</MedlinePgn></Pagination><Abstract><AbstractText>Pyrrolobenzoxazepinones (PBOs) represent a new class of human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) whose prototype is 5. Molecular modeling studies based on the X-ray structures of HIV-1 RT prompted the synthesis of novel analogues which were tested as anti-HIV agents. The PBO derivatives specifically designed to target the highly conserved amino acid residues within the beta12-beta13 hairpin, namely primer grip, proved to be very potent against the most common mutant enzymes, including the highly resistant K103N mutant strain. Structure-activity relationships (SARs) are discussed in terms of a possible interaction with the RT binding site, depending on the nature of the substituents at C-6. Among the pyrrolobenzoxazepines investigated, 15c appeared to be the most promising NNRTI of the series characterized by potent antiviral activity, broad spectrum, and low cytotoxicity. 15c showed synergistic antiviral activity with AZT.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fattorusso</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Dipartimento di Chimica delle Sostanze Naturali, Universita' di Napoli Federico II, via D. Montesano 49, 80131 Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gemma</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Butini</LastName><ForeName>Stefania</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Huleatt</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Catalanotti</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Persico</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>De Angelis</LastName><ForeName>Meri</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fiorini</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Nacci</LastName><ForeName>Vito</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Ramunno</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rodriquez</LastName><ForeName>Manuela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Greco</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Novellino</LastName><ForeName>Ettore</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bergamini</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Marini</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Coletta</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Maga</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Spadari</LastName><ForeName>Silvio</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Campiani</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Chem</MedlineTA><NlmUniqueID>9716531</NlmUniqueID><ISSNLinking>0022-2623</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010077">Oxazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>4B9XT59T7S</RegistryNumber><NameOfSubstance UI="D015215">Zidovudine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.49</RegistryNumber><NameOfSubstance UI="D054303">HIV Reverse Transcriptase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017124" MajorTopicYN="N">Conserved Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054303" MajorTopicYN="N">HIV Reverse Transcriptase</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010077" MajorTopicYN="N">Oxazepines</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N">Pyrroles</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018894" MajorTopicYN="N">Reverse Transcriptase Inhibitors</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013237" MajorTopicYN="N">Stereoisomerism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015215" MajorTopicYN="N">Zidovudine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16279773</ArticleId><ArticleId IdType="doi">10.1021/jm050257d</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="Bergamini, Alberto" sort="Bergamini, Alberto" uniqKey="Bergamini A" first="Alberto" last="Bergamini">Alberto Bergamini</name><name sortKey="Butini, Stefania" sort="Butini, Stefania" uniqKey="Butini S" first="Stefania" last="Butini">Stefania Butini</name><name sortKey="Campiani, Giuseppe" sort="Campiani, Giuseppe" uniqKey="Campiani G" first="Giuseppe" last="Campiani">Giuseppe Campiani</name><name sortKey="Catalanotti, Bruno" sort="Catalanotti, Bruno" uniqKey="Catalanotti B" first="Bruno" last="Catalanotti">Bruno Catalanotti</name><name sortKey="Coletta, Massimo" sort="Coletta, Massimo" uniqKey="Coletta M" first="Massimo" last="Coletta">Massimo Coletta</name><name sortKey="De Angelis, Meri" sort="De Angelis, Meri" uniqKey="De Angelis M" first="Meri" last="De Angelis">Meri De Angelis</name><name sortKey="Fiorini, Isabella" sort="Fiorini, Isabella" uniqKey="Fiorini I" first="Isabella" last="Fiorini">Isabella Fiorini</name><name sortKey="Gemma, Sandra" sort="Gemma, Sandra" uniqKey="Gemma S" first="Sandra" last="Gemma">Sandra Gemma</name><name sortKey="Greco, Giovanni" sort="Greco, Giovanni" uniqKey="Greco G" first="Giovanni" last="Greco">Giovanni Greco</name><name sortKey="Huleatt, Paul" sort="Huleatt, Paul" uniqKey="Huleatt P" first="Paul" last="Huleatt">Paul Huleatt</name><name sortKey="Maga, Giovanni" sort="Maga, Giovanni" uniqKey="Maga G" first="Giovanni" last="Maga">Giovanni Maga</name><name sortKey="Marini, Stefano" sort="Marini, Stefano" uniqKey="Marini S" first="Stefano" last="Marini">Stefano Marini</name><name sortKey="Nacci, Vito" sort="Nacci, Vito" uniqKey="Nacci V" first="Vito" last="Nacci">Vito Nacci</name><name sortKey="Novellino, Ettore" sort="Novellino, Ettore" uniqKey="Novellino E" first="Ettore" last="Novellino">Ettore Novellino</name><name sortKey="Persico, Marco" sort="Persico, Marco" uniqKey="Persico M" first="Marco" last="Persico">Marco Persico</name><name sortKey="Ramunno, Anna" sort="Ramunno, Anna" uniqKey="Ramunno A" first="Anna" last="Ramunno">Anna Ramunno</name><name sortKey="Rodriquez, Manuela" sort="Rodriquez, Manuela" uniqKey="Rodriquez M" first="Manuela" last="Rodriquez">Manuela Rodriquez</name><name sortKey="Spadari, Silvio" sort="Spadari, Silvio" uniqKey="Spadari S" first="Silvio" last="Spadari">Silvio Spadari</name></noCountry><country name="Italie"><noRegion><name sortKey="Fattorusso, Caterina" sort="Fattorusso, Caterina" uniqKey="Fattorusso C" first="Caterina" last="Fattorusso">Caterina Fattorusso</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001256 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001256 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:16279773
|texte= Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16279773" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |